Most Read Articles
Pearl Toh, 6 days ago
The prescription omega-3 fatty acid icosapent ethyl significantly reduces the need for revascularization in patients with elevated triglycerides who were already on statins and were at increased cardiovascular (CV) risk, reveals the latest data from the REDUCE-IT REVASC analysis presented during the SCAI* 2020 Meeting.
Audrey Abella, 07 Oct 2019
Individuals with left main coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) continued to show similar rates of the primary outcome (composite of death, stroke, or myocardial infarction), highlighting the potential of PCI as a CABG alternative in this patient setting, according to the final r­esults of the EXCEL* trial presented at TCT 2019.

Cocoa confers benefits for walking in older adults with peripheral artery disease

11 May 2020

Cocoa improves walking performance in elderly patients with peripheral artery disease (PAD), according to the results of a phase II trial.

The trial randomized 44 PAD patients (mean age, 72.3 years; 66 percent male; mean ankle brachial index, 0.66) to consume either a flavanol-rich cocoa beverage (n=23) or an identically appearing placebo beverage (n=21) thrice daily for 6 months. The cocoa beverage had 15 g of cocoa and 75 mg of epicatechin daily, while the placebo beverage contained neither.

Adherence rates, measured based on packet counts, were 68 percent in the cocoa group and 80 percent in the placebo group. Six-month change in epicatechin metabolites and theobromine was significantly greater in patients who drank cocoa, consistent with good adherence. A total of 40 patients (91 percent) completed follow-up.

At the 6-month follow-up, the 6-minute walking distance (6MWD) measured 2.5 hours after drinking the final study beverage improved by 42.6 metres with cocoa vs placebo (p=0.005). Cocoa consumption also improved the 6MWD measured 24 hours after final study beverage intake by 18.0 metres, although the difference was not significant relative to placebo (p=0.12).

In calf muscle biopsies, patients in the cocoa vs placebo group showed marked improvements in mitochondrial COX (cytochrome c oxidase) activity (p=0.013) and calf muscle perfusion (p=0.098), an increase in capillary density (p=0.014), and a reduction in central nuclei (p=0.033).

Further study is needed to establish the benefits of cocoa to patients with PAD.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
The prescription omega-3 fatty acid icosapent ethyl significantly reduces the need for revascularization in patients with elevated triglycerides who were already on statins and were at increased cardiovascular (CV) risk, reveals the latest data from the REDUCE-IT REVASC analysis presented during the SCAI* 2020 Meeting.
Audrey Abella, 07 Oct 2019
Individuals with left main coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) continued to show similar rates of the primary outcome (composite of death, stroke, or myocardial infarction), highlighting the potential of PCI as a CABG alternative in this patient setting, according to the final r­esults of the EXCEL* trial presented at TCT 2019.